|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
Investigation of the state of alpha-1 antitrypsin deficiency market, discussion of the regional variability of predisposing genotypes, disease description, pipeline details and factors hindering the development of new treatments.
Stakeholder Opinions: Female Sexual Dysfunction
Patients in a clinical population receive drug and non-drug therapy for female sexual dysfunction, yet a third remain refractory to treatment, highlighting a need for a formally approved product for FSD. There is a low level of satisfaction with the c
Stakeholder Opinions: Bone Metastases
Key issues in bone metastases, including mechanisms of normal and altered bone metabolism, epidemiology data, current treatment options, unmet needs, analysis of pipeline drugs in direct development for bone metastases and key stakeholder opinions.
Stakeholder Opinions: Multiple Myeloma
The incidence of multiple myeloma is forecast to total 40,885 cases across the seven major pharmaceutical markets in 2007. Current drug therapy is planned around stem cell transplantation. The recent approval of three new agentsThalomid (thalidomide;
Stakeholder Opinions: Sepsis
Key issues surrounding product development for sepsis, severe sepsis and septic shock. Analysis of the major clinical and commercial defining the four key areas of optimised individual treatment: predisposition, infection, response and organ failure.<
Stakeholder Opinion: Atopic Dermatitis
Investigates the epidemiology of atopic dermatitis and highlights the key unmet needs in the treatment of this disease. The current and future treatments of atopic dermatitis are discussed and the market controversies examined.
Stakeholder Opinions: Percutaneous Coronary Intervention
Physician opinion driven overview of percutaneous coronary intervention procedures and use of adjunctive therapies. The report covers the 7 major markets and reviews the market driving indications, treatment strategies, and drug eluting stents.
Stakeholder Opinions: Non-Hodgkins Lymphoma
Non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics. Treatment options in
Stakeholder Opinions: Esophageal Cancer
Examines key issues in the esophageal cancer market, including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into pipeline activity, and key stakeholder opinions.
Stakeholder Opinions: Biologics in Infectious Diseases
Explores key issues in the development of biologics for infectious diseases. It identifies promising targets, highlights development difficulties and gives an overview of antibacterial, antiviral and antifungal pipeline projects.
Stakeholder Opinions: Hepatitis C
Research and Development activity in the Hepatitis C arena continue to be high. The market still holds many areas of unmet medical needs: while existing therapies provide good efficacy for about half of the patient population, side effects and limited
Stakeholder Opinions: Portable Inhaler Devices
Comparative overview of portable inhaler devices used in the respiratory market. Gives insight into the current market situation based on IMS Sales Data. Assesses case studies to provide insight into potential market strategies.
Stakeholder Opinions: Hepatocellular Carcinoma
Key issues in hepatocellular carcinoma (HCC), including epidemiological forecasts, current treatment paradigms, unmet needs, drugs in late-stage development and key opinion leader insight.
Stakeholder Opinions: Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders. With a forecast incidence of 36,769 across the seven major markets in 2007, they are one of the most common hematological malignancies. Currently, the only
Stakeholder Opinions: Fibromyalgia
Mainly affecting women, fibromyalgia syndrome affects six million people in the US alone. This relatively common yet poorly understood syndrome is characterized by widespread muscle pain and fatigue and remains substantially underserved by the medical
Stakeholder Opinions: Primary Brain Cancer
Key issues in the primary brain cancer market, including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into pipeline activity and key stakeholder opinions. The report focuses in particular on glioma.
Non-hormonal Treatments for Menopausal Symptoms
This report provides analysis of the commercial and clinical potential of non-hormonal treatments for menopausal symptoms based on seven key opinion leader interviews, with focus on the treatment of vasomotor symptoms.
Stakeholder Opinions: Renal Cell Carcinoma - Novel Targeted...
A meager 20% of metastatic RCC tumors respond to standard cytokine therapy, thus rendering 80% of advanced RCC patients without any effective treatment. Further, with up to 50% of stage one to three patients relapsing following nephrectomy and an incr
Stakeholder Opinions: Sexually Transmitted Infections
The global incidence of STIs is estimated at several hundreds of millions cases per year, and due to the asymptomatic nature of most infections, underreporting is likely to mask the real incidence. Most STIs can lead to severe sequelae, including infer
Stakeholder Opinions: Chronic Leukemias - Curative Intent
Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innova
Stakeholder Opinions: Minimally Invasive Spinal Surgery...
As in other areas of surgery, surgeons are looking to reduce the invasive nature of spinal surgery, in an attempt to improve patient outcomes. The potential benefits of minimally invasive spinal surgery such as microdiscectomy and mini spinal fusion in
Stakeholder Opinions: HIV / HBV Co-infection
Long-term usage of HAART for the management of HIV has reduced mortality in the HIV-infected population. However, this has consequently led to an increase in the prevalence of chronic co-infections such as Hepatitis B (HBV). Currently, HBV prevalence
Stakeholder Opinions: Brain Metastases
The incidence of brain metastasis is escalating concurrent with improvements in systemic therapy increasing patient survival. There is no approved pharmacotherapy for these patients and current therapy is palliative. Median survival is four months. Th
Stakeholder Opinions: Migraine - Lots of Experience...
Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow phar
|
